Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Osteoporosis is a chronic disease and requires long-term treatment with pharmacologic therapy to ensure sustained antifracture benefit. Denosumab reduced the risk for new vertebral, nonvertebral, and hip fractures over 36 months in the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Brown, Jacques P, Roux, Christian, Törring, Ove, Ho, Pei-Ran, Beck Jensen, Jens-Erik, Gilchrist, Nigel, Recknor, Christopher, Austin, Matt, Wang, Andrea, Grauer, Andreas, Wagman, Rachel B
Format: Artigo
Langue:Inglês
Publié: Wiley Subscription Services, Inc., A Wiley Company 2013
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3617467/
https://ncbi.nlm.nih.gov/pubmed/23109251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.1808
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires